Introduction
1. Hsu MM, Tu SM.: Nasopharyngeal carcinoma in Taiwan, Clinical manifestations and results of therapy. Cancer 1983; 52:362-8.
2. Cvitkovic E for the International Nasopharynx Cancer Study Group. VUMCA I trial:
Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (>
or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Inter J Radiat Oncol Biol Physics 1996; 35(3): 463-9.
3. Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16(4): 1310-7.
4. Chua DT, Sham JS, Choy D, et al.: Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998; 83(11): 2270-83.
5. Cheng SH, Liu TW, Jian JJ, et al.: Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J From Scientific American 1997;
3(2): 100-6.
6. Chan ATC, Teo PML, Leung TWT, Leung SF, Lew WY, Teo W, Choi PHK, Johnson PJ.:
A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33:569-77.
7. Geara FB, Glisson BS, Sanguineti G, et al.: Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer 1997; 79(7): 1279-86.
8. Chan ATC, Teo PML, Johnson PJ: Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. Curr Opinion Oncol 1998; 10:219-55.
9. Fandi A, Altun M, Azli N, et al.: Nasopharyngeal cancer: Epidemiology, staging, and treatment. Semin Oncol 1994; 21:382-97.
10. Altun M, Fandi A, Dupuis O, et al.: Undifferentiated nasopharyngeal cancer (UCNT):
Current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995;
32:859-77.
11. Chan AT, Teo PM, Leung TW, Johnson PJ: The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer 1998; 82(6): 1003-12.
12. Teo PM, Kwan WH, Lee WY, et al.: Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996; 77:2423-31.
13. Hu OYP, Chang SP, Jame JM, Chen KY.: Pharmacokinetic and pharmacodynamic studies with 4’-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 1989; 24:332-7.
14. Chi KH, Chang YC, Chan WK, et al.: A phase II study of carboplatin in nasopharyngeal carcinoma. Oncology 1997; 54(3): 203-7.
15. Lin JM, Chan WK, Chi KH, et al.: Preliminary report of a phase II trial of ifofamide in patients with advanced stage nasopharyngeal carcinoma in Taiwan. Proc Am Soc Clin Oncol 1994; 13:285. (Abstr)
16. Bachouchi M, Cvitkovic E, Azli N, et al.: High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy.
J Natl Cancer Inst 1990; 82: 616-20.
17. Mahjoubi R, Azli N, Bachouchi M, et al.: Metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT) treated with bleomycin, epirubicin, and cisplatin (BEC).
Final report. Proc Am Soc Clin Oncol 1992; 11: 240. (Abstr)
18. Chi KH, Chan WK, Shu CH, et al.: Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin, using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 1996; 76: 2186-92.
19. Taamma A, Fandi A, Azli N, et al.: Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 1999; 86(7):
1101-8.
20. Tsai ST, Jin YT, Su IJ: Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization. A correlation with WHO histologic subtypes. Cancer 1996; 77:231-6.
Literature Review
1. Cheng AL, Su IJ, Chen YC, et al..: Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma. Cancer 1993; 72: 909-16.
2. Cheng AL, Su IJ, Chen YC, et al.: Expression of p-glycoprotein and glutathione-s-transferase in recurrent lymphoma: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11: 109-15.
3. Tsai ST, Jin YT, Su IJ: Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization. A correlation with WHO histological subtypes. Cancer 1996; 77:231-6.
4. De-Vathaire F, Sancho-Carnier H, De-The H, et al.: Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int J Cancer 1988; 42:176-81.
5. Yip TTC, Ngan RKC, Lau WH, et al.: A possible prognostic role of immunoglobulin-G
antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 1994; 74: 2414-24.
6. Dawson CW, Rickison AB, Young LS: Epstein-Barr virus latent protein inhibits human epithelial cell differentiation. Nature (London) 1990; 344:753-8.
7. Miller WE, Shelton Earp H, Raab-Traub N: The Epstein-Barr virus latent membrane protein induced expression of epidermal growth factor receptor. J Virol 1995;
69:4390-98.
8. Paine E, Scheiman RI, Baldwin AS Jr, Raab-Traub N: Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kB/Rel family protein. J Virol 1995;
69:4572-6.
9. Kieff E.: Epstein-Barr virus—increasing evidence of a link to carcinoma. (Editorial) New Engl J Med 1995; 333:724-6.
10. Mosialos G, Birkenbach M, Yalamanchili R, et al.: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for tumor necrosis factor family. Cell 1995;
80:389-99.
11. Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 274:782-4.
12. van Antwerp AAJ, Martin SJ, Kafri T, et al.: Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274:787-9.
13. Wang CY, Mayo MW, Baldwin AS Jr: TNF-and cancer therapy-induced apoptosis:
Potentiation by inhibition of NF-κB. Science 1996; 274:784-7.
14. Yang LS, Dawson CW, Eliopoulos AG: Viruses and apoptosis. Bri Med Bull 1997;
53:509-21.
15. Pearson GR, Luka J, Petti L, et al.: Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virol 1987;
160:151-61.
16. Khanim F, Dawson C, Meseda CA, et al.: BHRF-1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. J Gen Virol 1997; 78:2987-99.
17. Henderson S, Huen D, Rowe M, et al.: Epstein-Barr virus –coded BHRF-1 protein, a viral homologue of bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 1993; 90:8479-83.
18. Tarodi B, Subromanian T, Chinnadurai G: Epstein-Barr virus BHRF-1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection.
Virol 1994; 201:404-7.
19. Kawanishi M: Epstein-Barr virus BHRF-1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor alpha and anti-Fas antibody. J Virol 1997; 71:3319-22.
20. Liberman PM, Berk AJ: In Vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. J Virol 1990;
64:2560-2568.
21. Liberman PM, Hardwick JM, Sample J, et al.: The Zta transactivator involves in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol 1990;
64:1143-55.
22. Hu LF, Chen F, Zhen QF, et al.: Differences in the growth pattern and clinical course of EBV-LMP1 expressions and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995; 31A: 658-60.
23. Beck WT, Dalton WS: Mechanism of drug resistance. In Cancer; principles and practice of oncology. edited by Devita Jr.VT, Hellman S, Rosenberg SA. 5th ed.: pp 418-512, Lippincott-Raven Publishers. 1997.
24. Dive C, Hickman JA: Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991; 64:192-6.
25. Schinkel AH, Borst P: Multidrug resistance mediated by p-glycoprotein. Semin Cancer Biol 1991; 2:213-26.
26. Dietel M: What’s new in cytostatic drug resistance and pathology. Pathol Res Pract 1991;
187:892-905.
27. Chan HSL, Haddad G, Thorner PS, et al.: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325:1608-14.
28. Balddini N, Scotlandi K, Barbanit-Brodano G, et al.; Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1999;
333:1380-5.
29. O’Brien ML, Tew KD.: Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996; 2A(6): 967-78.
30. Nishio K, Nakamura T, Koh Y, et al.: Drug resistance in lung cancer. Cur Opinion Oncol 1999; 11:109-15.
31. Johnston PG, Fisher ER, Rochette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12:2640-7.
32. Johnston PG, Lenz HJ, Leichman CG, et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-12.
33. Yeh KH, Shun CT, Chen CL, et al.: High expression of thymidylate synthase is associated with drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82:1626-31.
34. Dumontet C, Sikic B.: Mechanisms of action and resistance to anti-tubulin agents:
microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17:1061-70.
35. Plunkett W, Haung P, Xu YZ, et al.: Gemcitabine: metabolism, mechanism of action, and self potentiation. Semin Oncol 1995; 22(Suppl 11): 3-10.
36. Ruiz van Haperen VW, Veerman G, Eriksson S, et al.: Induction of resistance to 2’,2’-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 1995; 22 (4 suppl 11): 35-41.
37. Neff T, Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1998; 24(11): 1340-6.
38. Eastman A.: Cancer Cells 1990; 2:275-80.
39. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 1996;
32A(6):921-6.
40. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 1994; 78:539-42.
41.Levine AJ, Momand J, Finlay CA.: The p53 tumor suppressor gene. Nature 1991;
351:453-456.
42. Lowe SW.: Cancer therapy and p53. Curr Opin Oncol 1995; 7:547-553.
43. Lowe SW, Bodis S, McClatchey A, et al.: P53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
44. Asa T, Borresen AL, Geisler S, et al.: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2:811-814.
45. Wattel E, Preudhomme C, Hecquat B, et al.: P53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood 1994;
84:3148-3157.
46. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 1997; 387:773-776.
47. Brown R.: The bcl-2 family of proteins. Bri Med Bulletin 1996; 53:466-77.
48. Sheu LF, Chen A, Meng CL, et al.: Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal carcinoma: association with p53 expression. Human Pathol 1997; 28(5):556-62.
49. Niedobitek G, Agathanggelou A, Barber P, et al.: P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 1993; 170(4):457-61.
50. Masuda M, Shinokuma A, Hirakawa N, et al.: Expression of bcl-2, p53, and ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head & Neck 1998; 20(7): 640-4.